← GLP-1 receptor agonists × body weight & composition

TrialDiabetologia2020

Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.

Maurice B Bizino et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT01761318. The trial’s primary report, PMID 31039778, speaks for it on the map; the numbers here are shown and do not vote.

Liraglutidelooks good hereLower body weight.Randomised, small.

What the trial testedrandomised · 50 people · 2020

Randomised vs placebo

Probably lowered body weight

Doesn’t vote: a later paper about the trial

−4.50−6.40 to −2.60

liraglutide vs placebo

As reported

difference −4.5, 95% CI −6.40 to −2.60

Range includes no effect

No clear effect on liver & MASLD

Doesn’t vote: a later paper about the trial

+0.03−0.09 to +0.04

As reported

difference 0.03, 95% CI −0.09 to 0.04

Who was studied, and how

50people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

liraglutide

placebo

Probably lowered body weight−4.50

randomised

the abstract, start to end

… (estimated mean treatment effect 0.03 [95% CI -0.09, 0.04], p …

… kg; estimated treatment effect -4.5 [95% CI -6.4, -2.6] kg).

← favours treatmentfavours comparator →

could be chance

Liver & masld

0.03−0.09 to 0.04

Body weightliraglutide vs placebo

−4.5−6.40 to −2.60

GLP-1 receptor agonistsBody weight & compositionLiver & MASLD

1 / 4

63 papers cite itlatest 60 shown

2020

…

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

The trial

NCT01761318phase 450 enrolled2013a later paper about it